SciSparc Ltd., a pharmaceutical company, was incorporated and started operations in Israel on August 23, 2004. The company is a clinical professional pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. Based on this, the company is currently working on the following development projects based on Δ 9-tetrahydrocannabinol (THC) and non-psychoactive cannabinol (CBD): THX-110 for the treatment of Tourette's syndrome (TS) and obstructive sleep apnea; THX-160 for the treatment of chronic and acute pain; and THX-210 for the treatment of chronic and acute pain, autism spectrum disorder and epilepsy.